KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AbCellera Biologics (ABCL) Current Taxes (2020 - 2022)

AbCellera Biologics' Current Taxes history spans 3 years, with the latest figure at $23.0 million for Q3 2022.

  • For the quarter ending Q3 2022, Current Taxes rose 249.29% year-over-year to $23.0 million, compared with a TTM value of $23.0 million through Sep 2022, up 249.29%, and an annual FY2021 reading of $35.7 million, down 1.3% over the prior year.
  • Current Taxes for Q3 2022 was $23.0 million at AbCellera Biologics, down from $107.3 million in the prior quarter.
  • The five-year high for Current Taxes was $107.3 million in Q2 2022, with the low at $5.8 million in Q2 2021.
  • Average Current Taxes over 3 years is $43.8 million, with a median of $32.9 million recorded in 2021.
  • Year-over-year, Current Taxes fell 1.3% in 2021 and then skyrocketed 1743.39% in 2022.
  • Tracing ABCL's Current Taxes over 3 years: stood at $36.2 million in 2020, then fell by 1.3% to $35.7 million in 2021, then plummeted by 35.49% to $23.0 million in 2022.
  • Per Business Quant, the three most recent readings for ABCL's Current Taxes are $23.0 million (Q3 2022), $107.3 million (Q2 2022), and $105.6 million (Q1 2022).